Elsevier

Gynecologic Oncology

Volume 78, Issue 3, September 2000, Pages 269-274
Gynecologic Oncology

Commentary
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer

https://doi.org/10.1006/gyno.2000.5926Get rights and content

Abstract

Due in most part to the abundant retrospective evidence suggesting that surgical cytoreduction is essential to the management of advanced ovarian cancer, most clinicians do not question its application. Irrespective, there are many who still doubt its value, given its unique role in ovarian cancer, in comparison to other solid tumors. While many papers have extolled the virtues of debulking surgery, few have taken the opposing view. This paper attempts to expose the weaknesses in the current available data regarding surgical cytoreduction in advanced ovarian cancer. By reviewing the retrospective data, the theoretical benefits of surgery, cellular kinetics, the fallacies of residual disease, interval debulking surgery, and neoadjuvant chemotherapy, a critique of debulking surgery is made. Issues surrounding perioperative morbidity and its impact on quality of life have not been adequately addressed. Despite the need for randomized trials of surgery in advanced ovarian cancer, they are unlikely to occur. The window of opportunity with respect to studying the questions on the optimal timing, degree of aggressiveness, and patient selection for surgery has likely passed. Biases and ethical issues based upon the data cited in this paper have and will continue to hamper our ability to fully elaborate the benefits of surgery with respect to survival and quality of life.

References (51)

  • WJ Hoskins

    The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer

    Bailliere's Clin Obstet Gynecol

    (1989)
  • SM Eisenkop et al.

    Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

    Gynecol Oncol

    (1998)
  • S LoCoco et al.

    Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian–American comparative study

    Gynecol Oncol

    (1995)
  • JG Blythe et al.

    Debulking surgery: does it increase the quality of survival?

    Gynecol Oncol

    (1982)
  • F Guidozzi et al.

    Extensive primary cytoreductive surgery of advanced epithelial ovarian cancer

    Gynecol Oncol

    (1994)
  • PE Schwartz et al.

    Neoadjuvant chemotherapy for advanced ovarian cancer

    Gynecol Oncol

    (1994)
  • JH Jacob et al.

    Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

    Gynecol Oncol

    (1991)
  • G Delgado et al.

    Stage III epithelial ovarian cancer: the role of maximal surgical reduction

    Gynecol Oncol

    (1984)
  • P Conte et al.

    Cisplatin, methotrexate and 5-fluorouracil combination chemotherapy for advanced ovarian cancer

    Gynecol Oncol

    (1985)
  • JG Posada et al.

    The cyclophosphamide, hexamethylmelamine, 5-fluorouracil regimen in the treatment of advanced and recurrent ovarian cancer

    Gynecol Oncol

    (1985)
  • JP Smith et al.

    Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute

    Am J Obstet Gynecol

    (1979)
  • JP Neijt et al.

    Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma

    Lancet

    (1984)
  • J Wharton et al.

    Cytoreductive surgery for common epithelial tumours of the ovary

    Clin Obstet Gynecol

    (1983)
  • CT Griffiths et al.

    Role of cytoreductive surgical treatment in the management of advanced ovarian cancer

    Cancer Treat Rep

    (1979)
  • G Michel et al.

    Extensive cytoreductive surgery in advanced ovarian carcinoma

    Eur J Gynecol Oncol

    (1997)
  • Cited by (168)

    View all citing articles on Scopus

    Presented at “Controversies in First-Line Therapy for Ovarian Carcinoma—Revisited,” Gynecologic Oncology Group Educational Symposium, July 16, 1998, Toronto, Canada.

    View full text